Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PBR06

Phase 3Small molecule

UUniversity Hospital, Bordeaux

PBR06 is one of 40 small molecule programs targeting Movement Disorder. It is currently in Phase 3.

2

Indications

10

Total Trials

1

Active Trials

39

Competitors

Pipeline

Status by Indication[3][1]

Indication

Movement DisorderActive, not recruiting

Multiple SclerosisCompleted

Movement DisorderPreclinical

Active, not recruiting

Multiple SclerosisPhase 3

Completed

Competition

Competitive Landscape

145 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Rinvoq

Cytoxan

BBaxter Healthcare Corporation

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Zyrtec

Clemastine Fumarate

Frexalimab

Activated Charcoal

Mayzent

MRI Contrast-Enhancing Agents

Tolebrutinib

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Multiple Sclerosis

NCT02649985

Clinical

Trials by Indication[1]

Multiple Sclerosis3 trials

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Recruiting·—·Phase 1/2·NCT02649985·250 enrolled

Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis

Withdrawn·—·Phase 1/2·NCT03983252

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

Completed·—·Phase 3·NCT04510220·10 enrolled

Movement Disorder1 trial

Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders

Unknown status·—··NCT05486806·50 enrolled

Imaging1 trial

Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA

Completed·—·Phase 1/2·NCT03033680·17 enrolled

Inflammation1 trial

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

Terminated·IInstitute for Neurodegenerative Disorders·Phase 1·NCT01028209·12 enrolled

Fatigue1 trial

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

Unknown status·—·Phase 1/2·NCT04144257·12 enrolled

3 more indications

ALS1 trial

Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET

Completed·MMolecular NeuroImaging·Phase 1·NCT03876002·23 enrolled

Stroke1 trial

Molecular Imaging of Inflammation With 18F-PBR06 to Identify Unstable Carotid Plaques in Patients With Stroke

Completed·UUniversity Hospital, Bordeaux·Phase 2·NCT02513589·3 enrolled

Unspecified1 trial

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

Completed·—·Phase 1·NCT04616456·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for PBR06. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PBR06 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PBR06. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Bordeaux company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Bordeaux

Related News